tirzepatide restrictions At a glance factsheet: for management of type 2 diabetes Starting tirzepatide earlier in #Type2Diabetes

Compounded formulations can offer more granular dose adjustments

Metformin is a generic drug

The final analysis used propensity score matching to narrow the data down to 18,386 patients9,183 prescribed each of the two medications

The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear

High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity